The analysis of DNA methylation in biological samples of patients. The combination of studied genes includes, among others, AKAP7, DFNA5, HSD17B2, MTRF1L, PLCG, RPS6KA1, STIM2, SULT1C2, TRABD, TRMT1, UST, and ZNRD1.
The analysis of transcriptional biomarkers that can predict patient response to immune-activating therapies, such as TLR9 inhibitors, including vidutolimod.
The development of diagnostic kits and devices for detecting urothelial tumors by assessing the methylation levels of these markers TRPS1, HAND2 and ZNF154.
The authors declare that they have no conflicts of interest.
Ethical approval
Not applicable.
Consent to participate
Not applicable.
Consent to publication
Not applicable.
Availability of data and materials
The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Leslie SW, Soon-Sutton TL, Aeddula NR. Bladder Cancer.In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. [PubMed]
Dobruch J, Oszczudłowski M. Bladder Cancer: Current Challenges and Future Directions.Medicina (Kaunas). 2021;57:749. [DOI] [PubMed] [PMC]
Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women.JAMA. 2011;306:737–45. [DOI] [PubMed] [PMC]
Teoh JY, Huang J, Ko WY, Lok V, Choi P, Ng CF, et al. Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita.Eur Urol. 2020;78:893–906. [DOI] [PubMed]
Wong MCS, Fung FDH, Leung C, Cheung WWL, Goggins WB, Ng CF. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection.Sci Rep. 2018;8:1129. [DOI] [PubMed] [PMC]
Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, et al. Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes.Eur Urol. 2016;69:300–10. [DOI] [PubMed]
Viswambaram P, Hayne D. Gender discrepancies in bladder cancer: potential explanations.Expert Rev Anticancer Ther. 2020;20:841–9. [DOI] [PubMed]
van Osch FH, Jochems SH, van Schooten FJ, Bryan RT, Zeegers MP. Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies.Int J Epidemiol. 2016;45:857–70. [DOI] [PubMed]
Martínez-Rojo E, Berumen LC, García-Alcocer G, Escobar-Cabrera J. The Role of Androgens and Androgen Receptor in Human Bladder Cancer.Biomolecules. 2021;11:594. [DOI] [PubMed] [PMC]
Del Sordo R, Covarelli C, Annese LC, Mandarano M, Bellezza G, Sidoni A. Urinary Diagnostic Cytology Beyond the Research of Neoplastic Cells: Usefulness of Erythrocyte Morphology Evaluation to Recognize Microhematuria Source.J Cytol. 2023;40:200–4. [DOI] [PubMed] [PMC]
Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L. Advances in diagnosis and treatment of bladder cancer.BMJ. 2024;384:e076743. [DOI] [PubMed]
Maas M, Bedke J, Stenzl A, Todenhöfer T. Can urinary biomarkers replace cystoscopy?World J Urol. 2019;37:1741–9. [DOI] [PubMed]
Kong T, Qu Y, Zhao T, Niu Z, Lv X, Wang Y, et al. Identification of novel protein biomarkers from the blood and urine for the early diagnosis of bladder cancer via proximity extension analysis.J Transl Med. 2024;22:314. [DOI] [PubMed] [PMC]
Ng K, Stenzl A, Sharma A, Vasdev N. Urinary biomarkers in bladder cancer: A review of the current landscape and future directions.Urol Oncol. 2021;39:41–51. [DOI] [PubMed]
Proctor I, Stoeber K, Williams GH. Biomarkers in bladder cancer.Histopathology. 2010;57:1–13. [DOI] [PubMed]
Dal Moro F, Valotto C, Guttilla A, Zattoni F. Urinary markers in the everyday diagnosis of bladder cancer.Urologia. 2013;80:265–75. [DOI] [PubMed]
Papavasiliou E, Sills VA, Calanzani N, Harrison H, Snudden C, di Martino E, et al. Diagnostic Performance of Biomarkers for Bladder Cancer Detection Suitable for Community and Primary Care Settings: A Systematic Review and Meta-Analysis.Cancers (Basel). 2023;15:709. [DOI] [PubMed] [PMC]
Oliveira MC, Caires HR, Oliveira MJ, Fraga A, Vasconcelos MH, Ribeiro R. Urinary Biomarkers in Bladder Cancer: Where Do We Stand and Potential Role of Extracellular Vesicles.Cancers (Basel). 2020;12:1400. [DOI] [PubMed] [PMC]
Lin J, Xu X, Li T, Yao J, Yu M, Zhu Y, et al. OLFML2B Is a Robust Prognostic Biomarker in Bladder Cancer Through Genome-Wide Screening: A Study Based on Seven Cohorts.Front Oncol. 2021;11:650678. [DOI] [PubMed] [PMC]
Zhou Q, Xu J, Chen X, Ouyang J, Mao C, Zhang Z. CD276 as a promising diagnostic and prognostic biomarker for bladder cancer through bioinformatics and clinical research.Front Oncol. 2024;14:1445526. [DOI] [PubMed] [PMC]
Krabbe LM, Gakis G, Lotan Y. Clinical Utility of Bladder Cancer Biomarkers.Soc Int Urol J. 2020;1:62–7. [DOI]
Bedore S, van der Eerden J, Boghani F, Patel SJ, Yassin S, Aguilar K, et al. Protein-Based Predictive Biomarkers to Personalize Neoadjuvant Therapy for Bladder Cancer-A Systematic Review of the Current Status.Int J Mol Sci. 2024;25:9899. [DOI] [PubMed] [PMC]
Bejrananda T, Saetang J, Sangkhathat S. Molecular Subtyping in Muscle-Invasive Bladder Cancer on Predicting Survival and Response of Treatment.Biomedicines. 2022;11:69. [DOI] [PubMed] [PMC]
Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.Cancer Res. 2003;63:8108–12. [PubMed]
Neuzillet Y, Paoletti X, Ouerhani S, Mongiat-Artus P, Soliman H, de The H, et al. A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer.PLoS One. 2012;7:e48993. [DOI] [PubMed] [PMC]
Nagata Y, Minato A, Aono H, Kimuro R, Higashijima K, Tomisaki I, et al. Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.Int J Mol Sci. 2024;25:10348. [DOI] [PubMed] [PMC]
Zhang X, Zhang Y. Bladder Cancer and Genetic Mutations.Cell Biochem Biophys. 2015;73:65–9. [DOI] [PubMed]
Sugita S, Enokida H, Yoshino H, Miyamoto K, Yonemori M, Sakaguchi T, et al. HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer.Int J Oncol. 2018;53:725–36. [DOI] [PubMed]
Manzano RG, Catalan-Latorre A, Brugarolas A. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.BMC Cancer. 2021;21:432. [DOI] [PubMed] [PMC]
Liu N, Wu T, Ma Y, Cheng H, Li W, Chen M. Identification and validation of RB1 as an immune-related prognostic signature based on tumor mutation burdens in bladder cancer.Anticancer Drugs. 2023;34:269–80. [DOI] [PubMed] [PMC]
Mao Z, Gao F, Sun T, Xiao Y, Wu J, Xiao Y, et al. RB1 Mutations Induce Smoking-Related Bladder Cancer by Modulating the Cytochrome P450 Pathway.Environ Toxicol. 2024;39:5357–70. [DOI] [PubMed]
Batista R, Vinagre N, Meireles S, Vinagre J, Prazeres H, Leão R, et al. Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review.Diagnostics (Basel). 2020;10:39. [DOI] [PubMed] [PMC]
Nunes SP, Henrique R, Jerónimo C, Paramio JM. DNA Methylation as a Therapeutic Target for Bladder Cancer.Cells. 2020;9:1850. [DOI] [PubMed] [PMC]
Koukourikis P, Papaioannou M, Georgopoulos P, Apostolidis I, Pervana S, Apostolidis A. A Study of DNA Methylation of Bladder Cancer Biomarkers in the Urine of Patients with Neurogenic Lower Urinary Tract Dysfunction.Biology (Basel). 2023;12:1126. [DOI] [PubMed] [PMC]
Fan T, Xue L, Dong B, He H, Zhang W, Hao L, et al. CDH1 overexpression predicts bladder cancer from early stage and inversely correlates with immune infiltration.BMC Urol. 2022;22:156. [DOI] [PubMed] [PMC]
Kim EJ, Jeong P, Quan C, Kim J, Bae SC, Yoon SJ, et al. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer.Urology. 2005;65:70–5. [DOI] [PubMed]
Kutwin P, Konecki T, Borkowska EM, Traczyk-Borszyńska M, Jabłonowski Z. Urine miRNA as a potential biomarker for bladder cancer detection - a meta-analysis.Cent European J Urol. 2018;71:177–85. [DOI] [PubMed] [PMC]
Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, Jocham D, et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer.Urol Oncol. 2010;28:655–61. [DOI] [PubMed]
Ghorbanmehr N, Gharbi S, Korsching E, Tavallaei M, Einollahi B, Mowla SJ. miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer.Prostate. 2019;79:88–95. [DOI] [PubMed]
Yamada Y, Enokida H, Kojima S, Kawakami K, Chiyomaru T, Tatarano S, et al. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology.Cancer Sci. 2011;102:522–9. [DOI] [PubMed]
Du L, Jiang X, Duan W, Wang R, Wang L, Zheng G, et al. Cell-free microRNA expression signatures in urine serve as novel noninvasive biomarkers for diagnosis and recurrence prediction of bladder cancer.Oncotarget. 2017;8:40832–42. [DOI] [PubMed] [PMC]
Cao Z, Xu L, Zhao S, Zhu X. The functions of microRNA-124 on bladder cancer.Onco Targets Ther. 2019;12:3429–39. [DOI] [PubMed] [PMC]
Li H, Li Y, Tian D, Zhang J, Duan S. miR-940 is a new biomarker with tumor diagnostic and prognostic value.Mol Ther Nucleic Acids. 2021;25:53–66. [DOI] [PubMed] [PMC]
Majid S, Dar AA, Saini S, Deng G, Chang I, Greene K, et al. MicroRNA-23b functions as a tumor suppressor by regulating Zeb1 in bladder cancer.PLoS One. 2013;8:e67686. [DOI] [PubMed] [PMC]
Mao Y, Wu S, Zhao R, Deng Q. MiR-205 promotes proliferation, migration and invasion of nasopharyngeal carcinoma cells by activation of AKT signalling.J Int Med Res. 2016;44:231–40. [DOI] [PubMed] [PMC]
Wang JM, Ju BH, Pan CJ, Gu Y, Li MQ, Sun L, et al. MiR-214 inhibits cell migration, invasion and promotes the drug sensitivity in human cervical cancer by targeting FOXM1.Am J Transl Res. 2017;9:3541–57. [PubMed] [PMC]
Zu C, Liu S, Cao W, Liu Z, Qiang H, Li Y, et al. MiR-590-3p suppresses epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma by inhibiting SIP1 expression.Oncotarget. 2017;8:34698–708. [DOI] [PubMed] [PMC]
Li J, Li H, Yang Y, Sen Y, Ye J. miRNA-143 as a potential biomarker in the detection of bladder cancer: a meta-analysis.Future Oncol. 2024;20:1275–87. [DOI] [PubMed] [PMC]
Chou R, Gore JL, Buckley D, Fu R, Gustafson K, Griffin JC, et al. Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis.Ann Intern Med. 2015;163:922–31. [DOI] [PubMed]
Sugeeta SS, Sharma A, Ng K, Nayak A, Vasdev N. Biomarkers in Bladder Cancer Surveillance.Front Surg. 2021;8:735868. [DOI] [PubMed] [PMC]
Matuszczak M, Salagierski M. Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers.Int J Mol Sci. 2020;21:3360. [DOI] [PubMed] [PMC]
Martínez-Piñeiro JA, Pertusa C, Maganto E, Zancajo VG, Magallon M, Losada G, et al. Urinary fibrinogen degradation products (FDP) in bladder cancer.Eur Urol. 1978;4:348–50. [DOI] [PubMed]
Ekberg M, Pandolfi M. Origin of urinary fibrin/fibrinogen degradation products in glomerulonephritis.Br Med J. 1975;2:17–9. [DOI] [PubMed] [PMC]
Qu K, Gu J, Ye Y, Williams SB, Dinney CP, Wu X, et al. High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis.Oncoimmunology. 2017;6:e1265719. [DOI] [PubMed] [PMC]
Urquidi V, Chang M, Dai Y, Kim J, Wolfson ED, Goodison S, et al. IL-8 as a urinary biomarker for the detection of bladder cancer.BMC Urol. 2012;12:12. [DOI] [PubMed] [PMC]
Escudero-Lourdes C, Wu T, Camarillo JM, Gandolfi AJ. Interleukin-8 (IL-8) over-production and autocrine cell activation are key factors in monomethylarsonous acid [MMA(III)]-induced malignant transformation of urothelial cells.Toxicol Appl Pharmacol. 2012;258:10–8. [DOI] [PubMed] [PMC]
Mousazadeh M, Nikkhah M. Advanced bladder cancer detection: Innovations in biomarkers and nanobiosensors.Sens Bio-Sens Res. 2024;45:100667. [DOI]
Wang R, Kang H, Zhang X, Nie Q, Wang H, Wang C, et al. Urinary metabolomics for discovering metabolic biomarkers of bladder cancer by UPLC-MS.BMC Cancer. 2022;22:214. [DOI] [PubMed] [PMC]
Rodrigues D, Jerónimo C, Henrique R, Belo L, de Lourdes Bastos M, de Pinho PG, et al. Biomarkers in bladder cancer: A metabolomic approach using in vitro and ex vivo model systems.Int J Cancer. 2016;139:256–68. [DOI] [PubMed]
Sahu D, Lotan Y, Wittmann B, Neri B, Hansel DE. Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer.Cancer Med. 2017;6:2106–20. [DOI] [PubMed] [PMC]
Jin X, Yun SJ, Jeong P, Kim IY, Kim WJ, Park S. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics.Oncotarget. 2014;5:1635–45. [DOI] [PubMed] [PMC]
Blick CG, Nazir SA, Mallett S, Turney BW, Onwu NN, Roberts IS, et al. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.BJU Int. 2012;110:84–94. [DOI] [PubMed]
Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TR, et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer.Health Technol Assess. 2010;14:1–331, iii. [DOI] [PubMed]
Kim TJ, Moon HW, Kang S, Yang J, Hong SH, Lee JY, et al. Urovysion FISH Could Be Effective and Useful Method to Confirm the Identity of Cultured Circulating Tumor Cells from Bladder Cancer Patients.J Cancer. 2019;10:3259–66. [DOI] [PubMed] [PMC]
Dimashkieh H, Wolff DJ, Smith TM, Houser PM, Nietert PJ, Yang J. Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation.Cancer Cytopathol. 2013;121:591–7. [DOI] [PubMed] [PMC]
Gutiérrez Baños JL, del Henar Rebollo Rodrigo M, Antolín Juárez FM, García BM. Usefulness of the BTA STAT Test for the diagnosis of bladder cancer.Urology. 2001;57:685–9. [DOI] [PubMed]
Raitanen MP; FinnBladder Group. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.World J Urol. 2008;26:45–50. [DOI] [PubMed]
Springer SU, Chen CH, Rodriguez Pena MDC, Li L, Douville C, Wang Y, et al. Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy.Elife. 2018;7:e32143. [DOI] [PubMed] [PMC]
Witjes JA, Morote J, Cornel EB, Gakis G, van Valenberg FJP, et al. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.Eur Urol Oncol. 2018;1:307–13. [DOI] [PubMed]
Trenti E, D’Elia C, Mian C, Schwienbacher C, Hanspeter E, Pycha A, et al. Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer.Cancer Cytopathol. 2019;127:465–9. [DOI] [PubMed]
O’Sullivan P, Sharples K, Dalphin M, Davidson P, Gilling P, Cambridge L, et al. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.J Urol. 2012;188:741–7. [DOI] [PubMed]
Valenberg FJPV, Hiar AM, Wallace E, Bridge JA, Mayne DJ, Beqaj S, et al. Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria.Eur Urol Oncol. 2021;4:93–101. [DOI] [PubMed]
Batista R, Vinagre J, Prazeres H, Sampaio C, Peralta P, Conceição P, et al. Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study.Front Genet. 2019;10:1237. [DOI] [PubMed] [PMC]
Nakanishi T, Yamamoto Y, Yamada K, inventor; UCL Business Ltd, assignee. Method for diagnosing bladder cancer through DNA methylation analysis.Patent No JP7002334B2. 2022 Jan 4.
Jiang Y, Guo Y, Gao W, Zhang J, Zhao W, Tian T, inventor; Third Hospital of Hebei Medical University, assignee. Application of gene marker combination in predicting prognosis of bladder urothelial cancer.Patent No CN115369173A. 2022 Nov 22.
Krieg A, Liu H, inventor. Transcriptional biomarkers for response to innate immune activators.Patent No WO2023130072A1. 2023 Jul 6.
Li Y, Song Q, Qin Q, Lin C, Wang X, Xu B, et al., inventor; Amoy Diagnostics Co Ltd, assignee. Marker for urothelial cancer and application thereof.Patent No CN117165688A. 2023 Dec 5.
Natarajan B, Bose S, Manoharan P, inventor. System and method for predicting diseases in its early phase using artificial intelligence.Patent No US20230248998A1. 2023 Aug 10.
Birkenkamp-Demtröder K, Christensen E, Nordentoft I, Knudsen M, Taber A, Høyer S, et al. Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis.Eur Urol. 2018;73:535–40. [DOI] [PubMed]
Kavalieris L, O’Sullivan P, Frampton C, Guilford P, Darling D, Jacobson E, et al. Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study.J Urol. 2017;197:1419–26. [DOI] [PubMed]
Rosser CJ, Chang M, Dai Y, Ross S, Mengual L, Alcaraz A, et al. Urinary protein biomarker panel for the detection of recurrent bladder cancer.Cancer Epidemiol Biomarkers Prev. 2014;23:1340–5. [DOI] [PubMed] [PMC]
Babu S, Mockler DC, Roa-Peña L, Szygalowicz A, Kim NW, Jahanfard S, et al. Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia.Mod Pathol. 2019;32:717–24. [DOI] [PubMed]
Vasdev N, Hampson A, Agarwal S, Swamy R, Chilvers M, Hampson A, et al. The role of URO17™ biomarker to enhance diagnosis of urothelial cancer in new hematuria patients-First European Data.BJUI Compass. 2020;2:46–52. [DOI] [PubMed] [PMC]
Mordente A, Meucci E, Martorana GE, Silvestrini A. Cancer Biomarkers Discovery and Validation: State of the Art, Problems and Future Perspectives.Adv Exp Med Biol. 2015;867:9–26. [DOI] [PubMed]
Frangogiannis NG. Biomarkers: hopes and challenges in the path from discovery to clinical practice.Transl Res. 2012;159:197–204. [DOI] [PubMed] [PMC]
Schwamborn K. Imaging mass spectrometry in biomarker discovery and validation.J Proteomics. 2012;75:4990–8. [DOI] [PubMed]
Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, et al.; EGAPP Working Group. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group.Genet Med. 2009;11:3–14. [DOI] [PubMed] [PMC]
Füzéry AK, Levin J, Chan MM, Chan DW. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges.Clin Proteomics. 2013;10:13. [DOI] [PubMed] [PMC]
Flores Monar GV, Reynolds T, Gordon M, Moon D, Moon C. Molecular Markers for Bladder Cancer Screening: An Insight into Bladder Cancer and FDA-Approved Biomarkers.Int J Mol Sci. 2023;24:14374. [DOI] [PubMed] [PMC]
Bhat A, Kwon D, Soodana-Prakash N, Mouzannar A, Punnen S, Gonzalgo ML, et al. Surveillance Intensity in Intermediate Risk, Nonmuscle Invasive Bladder Cancer: Revisiting the Optimal Timing and Frequency of Cystoscopy.J Urol. 2021;206:22–8. [DOI] [PubMed]
Svatek RS, Hollenbeck BK, Holmäng S, Lee R, Kim SP, Stenzl A, et al. The economics of bladder cancer: costs and considerations of caring for this disease.Eur Urol. 2014;66:253–62. [DOI] [PubMed]
Liu M, Li S, Rong Y, Long F, Zhao W, Qin Y, et al. Landscape of urine biomarkers for bladder cancer: molecular function, cell-of-origin, and bibliometric trend.Oncol Transl Med. 2024;10:132–42. [DOI]
